Literature DB >> 16609990

Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).

Christian Weissenberger1, Michael Geissler, Florian Otto, Annette Barke, Karl Henne, Georg von Plehn, Alex Rein, Christine Muller, Susanne Bartelt, Michael Henke.   

Abstract

AIM: To evaluate the long-term outcome of standard 5-FU based adjuvant or neoadjuvant radiochemotherapy and to identify the predictive factors, especially anemia before and after radiotherapy as well as hemoglobin increase or decrease during radiotherapy.
METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n=233) or preoperative (n=53) radiochemotherapy from January 1989 until July 2002. Overall survival (OAS), cancer-specific survival (CSS), disease-free survival (DFS), local-relapse-free (LRS) and distant-relapse-free survival (DRS) were evaluated using Kaplan-Meier, Log-rank test and Cox's proportional hazards as statistical methods. Multivariate analysis was used to identify prognostic factors. Median follow-up time was 8 years.
RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P=0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender. The univariate analysis revealed that anemia was associated with impaired LRS (better local control) but with improved DFS. In contrast, hemoglobin decrease during radiotherapy was an independent risk factor for DFS (risk ratio 1.97, P=0.04). During radiotherapy, only 30.8% of R0-resected patients suffered from hemoglobin decrease compared to 55.6% if R1/2 resection was performed (P=0.04). The 5-year OAS, CSS, DFS, LRS and DRS were 47.0%, 60.0%, 41.4%, 67.2%, and 84.3%, respectively. Significant differences between preoperative and postoperative radiochemotherapy were not found.
CONCLUSION: Anemia before radiochemotherapy and hemoglobin decrease during radiotherapy have no predictive value for the outcome of rectal cancer. Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16609990      PMCID: PMC4087509          DOI: 10.3748/wjg.v12.i12.1849

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

Review 1.  Treatment planning for adenocarcinoma of the rectum and sigmoid: a patterns of care study. PCS Committee.

Authors:  R W Kline; A R Smith; L R Coia; J B Owen; A Hanlon; M Wallace; G Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

2.  Adjuvant postoperative radiotherapy for adenocarcinoma of the rectum and rectosigmoid. A retrospective analysis of locoregional control, survival, and prognostic factors on 178 patients.

Authors:  H Martijn; W de Neve; M L Lybeert; M A Crommelin; J G Ribot
Journal:  Am J Clin Oncol       Date:  1995-08       Impact factor: 2.339

Review 3.  Analysis of local recurrence rates after surgery alone for rectal cancer.

Authors:  J L McCall; M R Cox; D A Wattchow
Journal:  Int J Colorectal Dis       Date:  1995       Impact factor: 2.571

Review 4.  Radical abdominopelvic lymphadenectomy: historic perspective and current role in the surgical management of rectal cancer.

Authors:  J R Harnsberger; V M Vernava; W E Longo
Journal:  Dis Colon Rectum       Date:  1994-01       Impact factor: 4.585

5.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

6.  Postoperative adjuvant radiotherapy in Astler-Coller stages B2 and C rectal cancer.

Authors:  R Tang; J Y Wang; J S Chen; C R Chang-Chien; S E Lin; S Leung; H A Fan
Journal:  Dis Colon Rectum       Date:  1992-11       Impact factor: 4.585

Review 7.  Pre-operative and post-operative radiotherapy and rectal cancer.

Authors:  L Påhlman; B Glimelius
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

8.  Blood hemoglobin level and treatment outcome of early breast cancer.

Authors:  Michael Henke; Florian Sindlinger; Hans Ikenberg; Thomas Gerds; Martin Schumacher
Journal:  Strahlenther Onkol       Date:  2004-01       Impact factor: 3.621

9.  Effective surgical adjuvant therapy for high-risk rectal carcinoma.

Authors:  J E Krook; C G Moertel; L L Gunderson; H S Wieand; R T Collins; R W Beart; T P Kubista; M A Poon; W C Meyers; J A Mailliard
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

10.  Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects.

Authors:  G J Frykholm; B Glimelius; L Påhlman
Journal:  Dis Colon Rectum       Date:  1993-06       Impact factor: 4.585

View more
  3 in total

1.  Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience.

Authors:  Robert Díaz Beveridge; Jorge Aparicio; Alejandro Tormo; Rafael Estevan; Josefina Artes; Alejandra Giménez; Ángel Segura; Susana Roldán; Rosana Palasí; David Ramos
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

2.  Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.

Authors:  Rafał Stec; Lubomir Bodnar; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

3.  Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival.

Authors:  Juha P Väyrynen; Anne Tuomisto; Sara A Väyrynen; Kai Klintrup; Toni Karhu; Jyrki Mäkelä; Karl-Heinz Herzig; Tuomo J Karttunen; Markus J Mäkinen
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.